Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

DNA Methylation Instability: A Novel Biomarker for Aging, Clonality, and Cancer

Salman Basrai, Robert Kridel, Mehran Bakhtiari, Dennis D. H. Kim, Fernando L. Scolari, Filio Billia, Andrea Arruda, Mark D. Minden, Sagi Abelson

Blood (2023) 142 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2023-173489

Published: 2023

Journal Articles

Chronic TNF in the Aging Microenvironment Exacerbates TET2- loss-of-Function Myeloid Expansion

Candice Quin, Erica DeJong, Amy J. M. McNaughton, Marco M. Buttigieg, Salman Basrai, Sagi Abelson, Margaret Larche, Michael J. Rauh, Dawn ME Bowdish

Blood (2023) 142 (Supplement 1): 938.

https://doi.org/10.1182/blood-2023-189163

Published: 2023

Journal Articles

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Gopila Gupta, May Chiu, Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Lucero, Daniela Zackova, Ivana Jeziskova, Anezka Kvetkova, Tomas Jurcek, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Jiri Mayer, Jessie Medeiros, Sagi Abelson, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4531.

https://doi.org/10.1182/blood-2023-189827

Published: 2023

Journal Articles

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Sahar Khan, Salman Basrai, Donna Reece, Sita D. Bhella, Vishal Kukreti, Anca Prica, A. Keith Stewart, Suzanne Trudel, Harjot Vohra, Chloe Yang, Sagi Abelson, Christine Chen

Blood (2023) 142 (Supplement 1): 760.

https://doi.org/10.1182/blood-2023-190978

Published: 2023

Journal Articles

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Blood (2023) 142 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2023-189797

Published: 2023

Journal Articles

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Blood (2022) 140 (Supplement 1): 6774–6775.

https://doi.org/10.1182/blood-2022-168228

Published: 2022

Journal Articles

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Blood (2022) 140 (Supplement 1): 6782–6783.

https://doi.org/10.1182/blood-2022-167927

Published: 2022

Journal Articles

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Taehyung Kim, Daniela Žácková, Ivana Ježíšková, Anežka Kvetková, Tomáš Jurček, Young Seok Yoo, Hyewon Lee, Kyoung Ha Kim, Myung Hee Chang, Seong Yoon Yi, Jessie J.F. Medeiros, Sagi Abelson, Dennis Kim

Blood (2022) 140 (Supplement 1): 812–814.

https://doi.org/10.1182/blood-2022-162676

Published: 2022

Journal Articles

Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

Sharon Ben Barouch, Tracy Lackraj, Jessie Medeiros, Mehran Bakhtiari, Jesse Joynt, Kit Tong, Andrea Arruda, Mark D. Minden, Mileidys Alvarez, John Kuruvilla, Sita Bhella, Vishal Kukreti, Michael Crump, Anca Prica, Christine I. Chen, Armand Keating, John E. Dick, Sagi Abelson, Robert Kridel

Blood (2021) 138 (Supplement 1): 655.

https://doi.org/10.1182/blood-2021-150102

Published: 2021

Journal Articles

Opposing Evolutionary Pressures Drive Clonal Evolution and Health Outcomes in the Aging Blood System

Kimberly Skead, Armande Ang Houle, Sagi Abelson, PhD, Marie-Julie Fave, PhD, Boxi Lin, David Soave, PhD, Stephen Wright, PhD, John E. Dick, PhD FRS, Quaid Morris, PhD, Phillip Awadalla, PhD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-142086

Published: 2020

Journal Articles

Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure

Stephanie C. Heidemann, MD, Brian Bursic, Sasan Zandi, MD PhD, Hongbing Li, PhD, Robert J Klaassen, MD FRCPC, Sharon Abish, MD, Meera Rayar, Vicky R. Breakey, BSc,MDFRCPC, Houtan Moshiri, PhD, Santhosh Dhanraj, PhD, Richard de Borja, PhD, Adam Shlien, PhD, John E. Dick, PhD, Yigal Dror, MDFRCPC, Sagi Abelson, PhD

Blood (2019) 134 (Supplement_1): 1223.

https://doi.org/10.1182/blood-2019-130534

Published: 2019

Journal Articles

Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome

Jian Chen, PhD, Yue Li, MD MSC, Fouad Yousif, Sagi Abelson, PhD, Sanaz Manteghi, PhD, John D. McPherson, PhD, Johann K. Hitzler, MD

Blood (2018) 132 (Supplement 1): 442.

https://doi.org/10.1182/blood-2018-99-117198

Published: 2018

Journal Articles

Developing Applicable and Cost-Efficient Screens for Early Detection of AML

Sagi Abelson, Stanley W.K. Ng, Ting Ting Wang, Scott V. Bratman, John E. Dick

Blood (2018) 132 (Supplement 1): 90.

https://doi.org/10.1182/blood-2018-99-113403

Published: 2018

Journal Articles

Progression to AML Is Predictable and Distinct from Age Related Clonal Hematopoiesis

Sagi Abelson, PhD, Stanley W.K. Ng, Omer Wiessbrod, Philip Zuzarte, Lawrence Heisler, Yogi Sundaravadanam, Ting Ting Wang, Trevor J. Pugh, PhD, David Soave, Paul Brennan, Mattias Johansson, Phillip Awadalla, Scott V. Bratman, Jean Wang, MD PhD, Mark D. Minden, MD PhD, John E. Dick, PhD, Liran I. Shlush

Blood (2017) 130 (Supplement 1): 471.

https://doi.org/10.1182/blood.V130.Suppl_1.471.471

Published: 2017

Journal Articles

Linking Subclonal Genetic Diversity with Functional Heterogeneity Identifies Diagnosis Subclones Destined to Relapse

Blood (2016) 128 (22): 605.

https://doi.org/10.1182/blood.V128.22.605.605

Published: 2016

Journal Articles

On the Origins of AML Relapse

Liran I. Shlush, MDPhD, Amanda Mitchell, PhD, Lawrence Heisler, PhD, Sagi Abelson, PhD, Monica Doedens, McLeod Jessica, Ms.C., John D. McPherson, PhD, Thomas Hudson, MD PhD, Jean C.Y. Wang, MDPhD, Mark D. Minden, MD PhD, John E. Dick, PhD

Blood (2015) 126 (23): 223.

https://doi.org/10.1182/blood.V126.23.223.223

Published: 2015

NARROW

DNA Methylation Instability: A Novel Biomarker for Aging, Clonality, and Cancer

Chronic TNF in the Aging Microenvironment Exacerbates TET2- loss-of-Function Myeloid Expansion

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

Opposing Evolutionary Pressures Drive Clonal Evolution and Health Outcomes in the Aging Blood System

Cellular and Molecular Architecture of Hematopoietic Stem Cells and Progenitors in Genetic Models of Bone Marrow Failure

Postnatally Acquired Mutations Underlie the Progression of Transient Leukemia to Myeloid Leukemia of Down Syndrome

Developing Applicable and Cost-Efficient Screens for Early Detection of AML

Progression to AML Is Predictable and Distinct from Age Related Clonal Hematopoiesis

Linking Subclonal Genetic Diversity with Functional Heterogeneity Identifies Diagnosis Subclones Destined to Relapse

On the Origins of AML Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only